BioInvent International ABBOVNF 53 PB Ratio is 4.59 as of Jul. 01, 2026, which is 62% above its 10-year median of 2.83. GuruFocus rates BOVNF with a GF Score™ of 53/100 and a GF Value™ of $6.77. The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, BioInvent International AB ranks worse than 60.13% on this metric.
The historical rank and industry rank for BioInvent International AB's PB Ratio or its related term are showing as below:
BOVNF'
s PB Ratio Range Over the Past 10 Years
Min: 0.68 Med: 2.83 Max: 9.61
Current: 3.62
During the past 13 years, BioInvent International AB's highest PB Ratio was 9.61. The lowest was 0.68. And the median was 2.83.
BOVNF's PB Ratio is ranked worse than 60.13% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs BOVNF: 3.62
During the past 12 months, BioInvent International AB's average Book Value Per Share Growth Rate was -43.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -15.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioInvent International AB was 56.30% per year. The lowest was -37.70% per year. And the median was -16.80% per year.
Back to Basics: PB Ratio
BioInvent International AB (OTCPK:BOVNF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioInvent International AB PB Ratio Related Terms
BioInvent International AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioInvent International AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioInvent International AB (BOVNF) has a PB Ratio of 4.59 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioInvent International AB and its competitors. This is 62% above median its historical median of 2.83. Over the past decade, BioInvent International AB's PB Ratio has ranged from 0.68 to 9.61. According to the industry distribution chart, BioInvent International AB ranks #739 out of 1229 companies in the Biotechnology industry, placing it in the top 60.1%.
Is BioInvent International AB's PB Ratio too high?
BioInvent International AB's current PB Ratio of 4.59 is 62% above median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 9.61. The Biotechnology industry median PB Ratio is 2.87. BioInvent International AB's value of 4.59 is 59.9% above this industry median. Based on the distribution chart, BioInvent International AB ranks #739 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #739 out of 1229 companies for PB Ratio. This places BioInvent International AB in the lower half of its industry. The industry median PB Ratio is 2.87. BioInvent International AB's value of 4.59 is 59.9% above this benchmark. Historically, BioInvent International AB's own PB Ratio has ranged from 0.68 to 9.61 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 2.87, BioInvent International AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioInvent International AB's current PB Ratio of 4.59 is 59.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioInvent International AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioInvent International AB's current PB Ratio is 4.59, which is 62% above median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current PB Ratio of 4.59. The stock's GF Value™ is $6.77, compared to a current price of $3.29 — trading 51.4% below its estimated fair value. The current PB Ratio is 4.59, which is 62% above median its 10-year median of 2.83 and 59.9% above the Biotechnology industry median of 2.87. BioInvent International AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current PB Ratio is 4.59 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.
Key valuation signals for BOVNF:
PB Ratio: 4.59 (62% above median its 10-year median of 2.83)
GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
Industry Position: 59.9% above the Biotechnology median (#739 of 1229)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
53GF Score
Get the complete analysis for BOVNF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
